Navigation Links
Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting
Date:5/7/2010

BALTIMORE, May 7 /PRNewswire/ -- A post-hoc analysis of a Phase 3 safety study demonstrated that NUCYNTA® (tapentadol) tablets were associated with a lower incidence of nausea, vomiting and constipation when compared to oxycodone immediate release (IR) tablets in elderly patients with moderate to severe low-back or osteoarthritis pain.  These data will be presented during a poster session today at the 29th Annual Scientific Meeting of the American Pain Society (APS), and are supported by PriCara®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., and its research affiliates, Ortho-McNeil-Janssen Scientific Affairs, L.L.C. (OMJSA) and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), as well as Grunenthal GmbH.

This post-hoc analysis of the original Phase 3 study evaluated the safety profile of tapentadol IR (n=158, either 50 or 100 mg dosed every four to six hours as needed) over a 90-day period among elderly patients (greater than or equal to 65 years of age).  The study also evaluated an oxycodone IR active comparator group (n=45, either 10 or 15 mg dosed every four to six hours as needed).

The analysis demonstrated that tapentadol IR was associated with lower incidences of specific gastrointestinal side effects versus oxycodone IR (46.8% vs. 68.9%, respectively) as well as lower incidences of study discontinuation due to gastrointestinal side effects versus oxycodone IR (15.8% vs. 24.4%, respectively). No significant between-age group differences in efficacy were observed for patients in the tapentadol IR group (P = 0.521 for patients less than 65 vs. patients greater than or equal to 65 years of age) or the oxycodone IR group (P = 0.987 for patients less than 65 vs. patients greater than or equal to 65 years of age).


'/>"/>
SOURCE PriCara,(R) Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. VerifyNow(R) System Highlighted in POPular Study Comparing Platelet Reactivity Tests
2. Complete Study Results Comparing CTIs OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
3. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
4. Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets
5. Telik Announces Initiation of Phase 1 Clinical Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Combination With Lenalidomide (Revlimid(R)) in Patients With Myelodysplastic Syndrome (MDS)
6. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
7. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
8. New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain
9. New Data: Cholesterol Management Analysis of Upsher-Smiths Slo-Niacin(R) Tablets in Combination with Lipitor(R)
10. Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants
11. Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... August 3, 2015 Global ... to reach USD 24.7 billion by 2022, according ... Inc. Growing prevalence of neurological and musculoskeletal disorders ... over the forecast period. The presence of efficient ... advancement in the technologies coupled with implementation of ...
(Date:8/3/2015)... RADNOR, Pa. , Aug. 3, 2015 ... of laboratory products, services and solutions, announces the redesign of ... its customers. When visiting the new site, ... site with bold colors and vivid images.  Each country site ... , an A to Z product menu; and , ...
(Date:8/3/2015)... 3, 2015  BioElectronics Corporation (OTC Pink: BIEL), maker ... that Andrew J. Whelan , President will be ... "On Business" at 9am EDT on Wednesday, August 5 ... to: http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ ... acceptance the company,s flagship product, ActiPatch Therapy, is achieving ...
Breaking Medicine Technology:Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 3Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 5VWR's New Website Redesign Provides Improved Functionality for Customers 2UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2
... Reportlinker.com announces that a new market research report ... Colorectal Cancer - France Drug Forecasts and Treatment ... Colorectal Cancer - France ... SummaryGlobalData, the industry analysis specialist, has ...
... West Booth# 19112 -- In anticipation of SupplySide West ... that it has entered into a strategic agreement with Mantrose-Haeuser ... distribution of its HIDROX® products, used in dietary supplement and ... "We are looking at the market for dietary supplements and ...
Cached Medicine Technology:Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 2Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 3Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 4Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 5Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 6Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 7Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 8Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 9Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 10Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 11Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 12Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 13Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 14Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 15CREAGRI Partners With Mantrose-Haeuser Co., Inc. for the Distribution of Its HIDROX® 2CREAGRI Partners With Mantrose-Haeuser Co., Inc. for the Distribution of Its HIDROX® 3
(Date:8/3/2015)... Angeles, CA (PRWEB) , ... August 03, 2015 , ... According to an opinion ... calories out of person’s diet leads to one pound of weight loss may not be ... caloric reduction that translates to one pound of fat varies – based both on the ...
(Date:8/3/2015)... Princeton, NJ (PRWEB) , ... August 03, 2015 ... ... named a finalist in 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs ... by and for B2B brands. BESLER Consulting's campaign for the launch of their ...
(Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... ... Hispanic Health notes that while an overwhelming number of Hispanics believe people ... , The overwhelming 70 percent of participants queried said making diet changes was ...
(Date:8/3/2015)... ... August 03, 2015 , ... Social impact organization’s #HelpOneHelpMany ... 2015 – Since winning a South by Southwest® (SXSW®) Interactive Innovation Award in ... whose mission is to develop technology for the sake of humanity – continues ...
(Date:8/3/2015)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions ... Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker Meridien in New York, ... be accessed via the investor relations section of the Company’s website. , About AxoGen, ...
Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2
... Goal of 40 million doses by end of October won,t ... -- Production delays continue to hamper distribution of the H1N1 ... , The vaccine is growing more slowly in egg-based cultures ... this time, Dr. Thomas R. Frieden, director of the U.S. ...
... heart patients when ARB added to ACE inhibitor therapy, study ... angiotensin receptor blocker (ARB) drug to help control blood pressure ... are taking an ACE inhibitor, a new study finds. , ... therapy seems no better than ACE inhibitor therapy alone and ...
... lower-than-normal levels of a naturally-occurring fat hormone may increase ... the blood which claims thousands of lives each year. ... Hospital and the University of Toronto focused on adiponectin, ... organs. The findings were presented this week at the ...
... new Commonwealth Fund report analyzes the similarities, differences, potential ... five committees of jurisdiction in the United States Congress: ... Committees in the Senate and the U.S. House of ... and Commerce committees. The report, Provisions of Comprehensive ...
... research finds that mother,s drug use affects male offspring,s behavior ... monkeys exposed to cocaine in the womb have poor impulse ... research has found. , The male monkeys continued to have ... risk factor for drug abuse, said the researchers, who added ...
... More than half the people who take antidepressants for depression ... depression has been oversimplified and drugs designed to treat it ... the Northwestern University Feinberg School of Medicine. The medications are ... eye instead of the center. A study from ...
Cached Medicine News:Health News:Swine Flu Vaccine Still in Short Supply 2Health News:Swine Flu Vaccine Still in Short Supply 3Health News:Adding Drug Doesn't Help Control Blood Pressure 2Health News:Canadian scientists link fat hormone to death from potentially deadly blood infection 2Health News:Analysis of Congressional health reform bills highlights similarities, differences, costs 2Health News:Cocaine Use in Pregnancy Linked to Impulsivity in Sons 2Health News:Why antidepressants don't work for so many 2Health News:Why antidepressants don't work for so many 3
Bechert-McPherson tying forceps, angled, 10 mm tying platforms....
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Girard curved tying forceps made of titanium has curved shafts with 8 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 99 mm....
Girard straight tying forceps made of titanium has straight shafts with 6 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 105 mm....
Medicine Products: